These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9145456)

  • 1. A clinical hepatologist's predictions about non-absorbed carbohydrates for the early twenty-first century.
    Conn HO
    Scand J Gastroenterol Suppl; 1997; 222():88-92. PubMed ID: 9145456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lactulose, disaccharides and colonic flora. Clinical consequences.
    Clausen MR; Mortensen PB
    Drugs; 1997 Jun; 53(6):930-42. PubMed ID: 9179525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
    Sharma BC; Sharma P; Lunia MK; Srivastava S; Goyal R; Sarin SK
    Am J Gastroenterol; 2013 Sep; 108(9):1458-63. PubMed ID: 23877348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy.
    Watanabe A; Sakai T; Sato S; Imai F; Ohto M; Arakawa Y; Toda G; Kobayashi K; Muto Y; Tsujii T; Kawasaki H; Okita K; Tanikawa K; Fujiyama S; Shimada S
    Hepatology; 1997 Dec; 26(6):1410-4. PubMed ID: 9397979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of nonresponse to lactulose in patients with cirrhosis and hepatic encephalopathy.
    Sharma P; Sharma BC; Sarin SK
    Eur J Gastroenterol Hepatol; 2010 May; 22(5):526-31. PubMed ID: 20009938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lactulose and combination therapy of hepatic encephalopathy: the role of the intestinal microflora.
    Weber FL
    Dig Dis; 1996; 14 Suppl 1():53-63. PubMed ID: 8872452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Lactulose and its derivatives--treatment of hepatic encephalopathy and other possible indications for its use].
    Fehér J; Prónai L
    Orv Hetil; 1993 Jun; 134(26):1417-9. PubMed ID: 8332363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose.
    Sharma P; Sharma BC; Agrawal A; Sarin SK
    J Gastroenterol Hepatol; 2012 Aug; 27(8):1329-35. PubMed ID: 22606978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy.
    Horsmans Y; Solbreux PM; Daenens C; Desager JP; Geubel AP
    Aliment Pharmacol Ther; 1997 Feb; 11(1):165-70. PubMed ID: 9042989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of lactulose treatment on the course of subclinical hepatic encephalopathy].
    Zeng Z; Li YY
    Zhonghua Yi Xue Za Zhi; 2003 Jul; 83(13):1126-9. PubMed ID: 12921628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy.
    Agrawal A; Sharma BC; Sharma P; Sarin SK
    Am J Gastroenterol; 2012 Jul; 107(7):1043-50. PubMed ID: 22710579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical, nutritional and technological properties of lactulose. An update.
    Schumann C
    Eur J Nutr; 2002 Nov; 41 Suppl 1():I17-25. PubMed ID: 12420112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
    Irimia R; Trifan A
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of lactulose in the prophylaxis of hepatic encephalopathy in cirrhotic patients presenting gastrointestinal bleeding.
    Aires FT; Ramos PT; Bernardo WM
    Rev Assoc Med Bras (1992); 2016; 62(3):243-7. PubMed ID: 27310548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Reduction of hospital stay with the use of L-ornithine L-aspartate (LOLA) in patients with hepatic encephalopathy].
    Abdo-Francis JM; Pérez-Hernández JL; Hinojosa-Ruiz A; Hernández-Vásquez JR
    Rev Gastroenterol Mex; 2010; 75(2):135-41. PubMed ID: 20615780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lactulose treatment for hepatic encephalopathy, gastrointestinal symptoms, and health-related quality of life.
    Kalaitzakis E; Björnsson E
    Hepatology; 2007 Sep; 46(3):949-50; author reply 951. PubMed ID: 17879365
    [No Abstract]   [Full Text] [Related]  

  • 17. Optimal treatment of hepatic encephalopathy.
    Waghray A; Waghray N; Kanna S; Mullen K
    Minerva Gastroenterol Dietol; 2014 Mar; 60(1):55-70. PubMed ID: 24632768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis.
    Huang E; Esrailian E; Spiegel BM
    Aliment Pharmacol Ther; 2007 Oct; 26(8):1147-61. PubMed ID: 17894657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo.
    Sharma BC; Sharma P; Agrawal A; Sarin SK
    Gastroenterology; 2009 Sep; 137(3):885-91, 891.e1. PubMed ID: 19501587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo lactose and lactulose effects on colonic fermentation and portal-systemic encephalopathy parameters.
    Uribe-Esquivel M; Moran S; Poo JL; Muñoz RM
    Scand J Gastroenterol Suppl; 1997; 222():49-52. PubMed ID: 9145447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.